Type 2 Diabetes

A study assesses whether the dual sodium–glucose co-transporter (SGLT) 1/2 inhibitor sotagliflozin reduces ischemic events in diabetes and kidney disease.

Individuals with prediabetes who achieve a weight loss of at least 5% experience significant improvements in insulin sensitivity and reductions in visceral fat, suggesting that remission of prediabetes can...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing patients with diabetes and the value of utilizing the services of a...

Researchers examined the risk of nephrolithiasis among patients with type 2 diabetes using SGLT2is for treatment.

Researchers investigated semaglutide’s impact on weight-related muscle loss and its potential impact on spinal surgical outcomes, specifically transforaminal lumbar interbody fusion.

Researchers sought to determine whether patients with type 2 diabetes and obesity experience continued type 2 diabetes remission.

On March 8, the FDA approved the injectable weight loss medication, semaglutide, for reducing the risk of cardiovascular events such as heart attack, stroke, and cardiovascular death in adults with heart...

In this Roundtable Wrap-Up, we offer an abbreviated version of the roundtable discussion on the multidisciplinary approach to managing people with diabetes, the importance of diabetes self-care and...

Researchers evaluated the popular diabetes medication, semaglutide, to determine whether it causes or worsens diabetic retinopathy in patients using the medication. Their findings were presented at AAO 2023...

Researchers compared the effects of once-weekly semaglutide (2.4 mg) with a placebo during a 52-week period in patients with HFpEF and a BMI of 30 or higher.